Blood Journal
Leading the way in experimental and clinical research in hematology

Pursuing the curative blueprint for early myeloma

  1. Mark Roschewski,
  2. Neha Korde,
  3. S. Peter Wu, and
  4. Ola Landgren*
  1. 1 Multiple Myeloma Section, Center for Cancer Research, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
  1. * Corresponding author; email: landgreo{at}


Treatment philosophies in multiple myeloma (MM) debate the relative merits of achieving deepest possible remissions ("curative" doctrine) versus sequential delivery of anti-myeloma agents ("control" doctrine). In this Spotlight, we highlight the relevant strengths of each doctrine in the context of modern patient selection strategies, fresh biologic insights on MM pathogenesis, agents with improved safety profiles, and emerging molecular and imaging tools. Paramount fundamental questions remain unanswered that require intense research focus as we pursue a cure of this devastating disease.

  • Submitted January 28, 2013.
  • Accepted June 16, 2013.